Selected research
Industry Research
Oligonucleotide Drug CDMO Services Industry Research Report 2026
Market perspective
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oligonucleotide Drug CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oligonucleotide Drug CDMO Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oligonucleotide Drug CDMO Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oligonucleotide Drug CDMO Services include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma and Cytiva, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oligonucleotide Drug CDMO Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oligonucleotide Drug CDMO Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oligonucleotide Drug CDMO Services Market by Company
Bachem
WuXi TIDES
Ajinomoto Co
Waters
AGC Biologics
Merck KGaA
EUROAPI
CordenPharma
Cytiva
TriLink BioTechnologies
Medicilon
General Biol
BioSpring
Bio-Synthesis Inc
Aurisco
Suzhou Olipharma Co.,Ltd
Porton
RIBOPharm
Oligonucleotide Drug CDMO Services Segment by Type
API
Preparation
Oligonucleotide Drug CDMO Services Segment by Application
SME Pharmaceutical Company
Large Pharmaceutical Company
Oligonucleotide Drug CDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Drug CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Drug CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Drug CDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oligonucleotide Drug CDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- API
- Preparation
Applications
- SME Pharmaceutical Company
- Large Pharmaceutical Company
Companies covered
- Bachem
- WuXi TIDES
- Ajinomoto Co
- Waters
- AGC Biologics
- Merck KGaA
- EUROAPI
- CordenPharma
- Cytiva
- TriLink BioTechnologies
- Medicilon
- General Biol
- BioSpring
- Bio-Synthesis Inc
- Aurisco
- Suzhou Olipharma Co.,Ltd
- Porton
- RIBOPharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oligonucleotide Drug CDMO Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 API
- 2.2.3 Preparation
- 2.3 Oligonucleotide Drug CDMO Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 SME Pharmaceutical Company
- 2.3.3 Large Pharmaceutical Company
- 2.4 Assumptions and Limitations
3 Oligonucleotide Drug CDMO Services Breakdown Data by Type
- 3.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Type (2021-2026)
- 3.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2027-2032)
4 Oligonucleotide Drug CDMO Services Breakdown Data by Application
- 4.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Application (2021-2026)
- 4.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oligonucleotide Drug CDMO Services Market Perspective (2021-2032)
- 5.2 Global Oligonucleotide Drug CDMO Services Growth Trends by Region
- 5.2.1 Global Oligonucleotide Drug CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oligonucleotide Drug CDMO Services Historic Market Size by Region (2021-2026)
- 5.2.3 Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (2027-2032)
- 5.3 Oligonucleotide Drug CDMO Services Market Dynamics
- 5.3.1 Oligonucleotide Drug CDMO Services Industry Trends
- 5.3.2 Oligonucleotide Drug CDMO Services Market Drivers
- 5.3.3 Oligonucleotide Drug CDMO Services Market Challenges
- 5.3.4 Oligonucleotide Drug CDMO Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue
- 6.1.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue (2021-2026)
- 6.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Oligonucleotide Drug CDMO Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oligonucleotide Drug CDMO Services Head Office and Area Served
- 6.4 Global Oligonucleotide Drug CDMO Services Players, Product Type & Application
- 6.5 Global Oligonucleotide Drug CDMO Services Manufacturers Established Date
- 6.6 Global Oligonucleotide Drug CDMO Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oligonucleotide Drug CDMO Services Market Size (2021-2032)
- 7.2 North America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
- 7.4 North America Oligonucleotide Drug CDMO Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oligonucleotide Drug CDMO Services Market Size (2021-2032)
- 8.2 Europe Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
- 8.4 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size (2021-2032)
- 9.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oligonucleotide Drug CDMO Services Market Size (2021-2032)
- 10.2 South America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
- 10.4 South America Oligonucleotide Drug CDMO Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size (2021-2032)
- 11.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bachem
- 12.1.1 Bachem Company Information
- 12.1.2 Bachem Business Overview
- 12.1.3 Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.1.4 Bachem Oligonucleotide Drug CDMO Services Product Portfolio
- 12.1.5 Bachem Recent Developments
- 12.2 WuXi TIDES
- 12.2.1 WuXi TIDES Company Information
- 12.2.2 WuXi TIDES Business Overview
- 12.2.3 WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.2.4 WuXi TIDES Oligonucleotide Drug CDMO Services Product Portfolio
- 12.2.5 WuXi TIDES Recent Developments
- 12.3 Ajinomoto Co
- 12.3.1 Ajinomoto Co Company Information
- 12.3.2 Ajinomoto Co Business Overview
- 12.3.3 Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.3.4 Ajinomoto Co Oligonucleotide Drug CDMO Services Product Portfolio
- 12.3.5 Ajinomoto Co Recent Developments
- 12.4 Waters
- 12.4.1 Waters Company Information
- 12.4.2 Waters Business Overview
- 12.4.3 Waters Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.4.4 Waters Oligonucleotide Drug CDMO Services Product Portfolio
- 12.4.5 Waters Recent Developments
- 12.5 AGC Biologics
- 12.5.1 AGC Biologics Company Information
- 12.5.2 AGC Biologics Business Overview
- 12.5.3 AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.5.4 AGC Biologics Oligonucleotide Drug CDMO Services Product Portfolio
- 12.5.5 AGC Biologics Recent Developments
- 12.6 Merck KGaA
- 12.6.1 Merck KGaA Company Information
- 12.6.2 Merck KGaA Business Overview
- 12.6.3 Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.6.4 Merck KGaA Oligonucleotide Drug CDMO Services Product Portfolio
- 12.6.5 Merck KGaA Recent Developments
- 12.7 EUROAPI
- 12.7.1 EUROAPI Company Information
- 12.7.2 EUROAPI Business Overview
- 12.7.3 EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.7.4 EUROAPI Oligonucleotide Drug CDMO Services Product Portfolio
- 12.7.5 EUROAPI Recent Developments
- 12.8 CordenPharma
- 12.8.1 CordenPharma Company Information
- 12.8.2 CordenPharma Business Overview
- 12.8.3 CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.8.4 CordenPharma Oligonucleotide Drug CDMO Services Product Portfolio
- 12.8.5 CordenPharma Recent Developments
- 12.9 Cytiva
- 12.9.1 Cytiva Company Information
- 12.9.2 Cytiva Business Overview
- 12.9.3 Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.9.4 Cytiva Oligonucleotide Drug CDMO Services Product Portfolio
- 12.9.5 Cytiva Recent Developments
- 12.10 TriLink BioTechnologies
- 12.10.1 TriLink BioTechnologies Company Information
- 12.10.2 TriLink BioTechnologies Business Overview
- 12.10.3 TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.10.4 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Portfolio
- 12.10.5 TriLink BioTechnologies Recent Developments
- 12.11 Medicilon
- 12.11.1 Medicilon Company Information
- 12.11.2 Medicilon Business Overview
- 12.11.3 Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.11.4 Medicilon Oligonucleotide Drug CDMO Services Product Portfolio
- 12.11.5 Medicilon Recent Developments
- 12.12 General Biol
- 12.12.1 General Biol Company Information
- 12.12.2 General Biol Business Overview
- 12.12.3 General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.12.4 General Biol Oligonucleotide Drug CDMO Services Product Portfolio
- 12.12.5 General Biol Recent Developments
- 12.13 BioSpring
- 12.13.1 BioSpring Company Information
- 12.13.2 BioSpring Business Overview
- 12.13.3 BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.13.4 BioSpring Oligonucleotide Drug CDMO Services Product Portfolio
- 12.13.5 BioSpring Recent Developments
- 12.14 Bio-Synthesis Inc
- 12.14.1 Bio-Synthesis Inc Company Information
- 12.14.2 Bio-Synthesis Inc Business Overview
- 12.14.3 Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.14.4 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Portfolio
- 12.14.5 Bio-Synthesis Inc Recent Developments
- 12.15 Aurisco
- 12.15.1 Aurisco Company Information
- 12.15.2 Aurisco Business Overview
- 12.15.3 Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.15.4 Aurisco Oligonucleotide Drug CDMO Services Product Portfolio
- 12.15.5 Aurisco Recent Developments
- 12.16 Suzhou Olipharma Co.,Ltd
- 12.16.1 Suzhou Olipharma Co.,Ltd Company Information
- 12.16.2 Suzhou Olipharma Co.,Ltd Business Overview
- 12.16.3 Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.16.4 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Portfolio
- 12.16.5 Suzhou Olipharma Co.,Ltd Recent Developments
- 12.17 Porton
- 12.17.1 Porton Company Information
- 12.17.2 Porton Business Overview
- 12.17.3 Porton Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.17.4 Porton Oligonucleotide Drug CDMO Services Product Portfolio
- 12.17.5 Porton Recent Developments
- 12.18 RIBOPharm
- 12.18.1 RIBOPharm Company Information
- 12.18.2 RIBOPharm Business Overview
- 12.18.3 RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2021-2026)
- 12.18.4 RIBOPharm Oligonucleotide Drug CDMO Services Product Portfolio
- 12.18.5 RIBOPharm Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst